Short Interest in Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) Decreases By 58.3%

Towa Pharmaceutical Co., Ltd. (OTCMKTS:TWAPF) was the target of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 1,630 shares, a decline of 58.3% from the July 15th total of 3,905 shares. Based on an average trading volume of 20 shares, the short-interest ratio is presently 81.5 days.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Towa Pharmaceutical to an “overweight” rating in a research report on Friday, June 12th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy”.

Towa Pharmaceutical Stock Performance

OTCMKTS:TWAPF opened at $25.98 on Friday. Towa Pharmaceutical has a twelve month low of $25.71 and a twelve month high of $26.00. The stock has a fifty day simple moving average of $25.72 and a 200-day simple moving average of $25.47.

Towa Pharmaceutical Company Profile

Towa Pharmaceutical Co, Ltd. (OTCMKTS:TWAPF) is a Japan-based healthcare company primarily engaged in the research, development, manufacturing and sale of pharmaceutical products. The company’s product portfolio spans active pharmaceutical ingredients (APIs), finished dosage forms such as tablets and capsules, and over-the-counter (OTC) preparations. Towa Pharmaceutical serves both prescription and consumer healthcare markets, offering formulations that address chronic conditions, lifestyle-related illnesses and general wellness.

In addition to its in-house product lines, Towa Pharmaceutical provides contract manufacturing and development services to domestic and international partners.